Search results
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 7 days agoDr. Edwards is a seasoned drug discovery leader with extensive...
Hearst Health Prize judging panel selects two fina | Newswise
Newswise· 7 days agoThe winner will be announced at UCLA Health Data Day on June 4, 2024. The Hearst Health Prize showcases data science programs ...
US Universities Expand Climate Change Degree Offerings Amid Growing Demand | KQED
KQED· 11 hours agoOther early movers that created programs, majors, minors and certificates dedicated to climate...
The top five states people never want to move away from — and the ones they always leave
The Independent via Yahoo News· 26 minutes agoStates like Texas, North Carolina, Georgia, Utah and California do better than anyone else at...
Community science volunteers can set scientific world abuzz with new bumble bee sightings
Phys.org· 5 days agoIt is buzz-worthy confirmation that community science programs can play an important role in...
Mississippi State to offer artificial intelligence degree in the fall: Jobs for the future
Gannett via AOL· 4 days agoIt will be offered beginning in the fall through the computer science and engineering department and...
NASA Open Science Funding Opportunities - NASA Science
NASA· 3 days agoNASA offers a number of opportunities in the Research Opportunities for Space and Earth Science...
UAMS officials looking to start certified nurse midwifery program in 2026 | Arkansas Democrat...
Arkansas Democrat-Gazette· 1 day agoOfficials at the University of Arkansas for Medical Sciences are aiming to start a two-year...
Tennessee Tech Launches New Degree Program in Nuclear Engineering
POWER Magazine via Yahoo Finance· 6 days agoThe College of Engineering at Tennessee Tech University announced on May 21 the launch of its...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
FOX 5 San Diego· 2 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...